Tirbanibulin: review of its novel mechanism of action and how it fits into the treatment of actinic keratosis.
Tirbanibulina: revisión de su mecanismo de acción novedoso y de cómo encaja en el tratamiento de la queratosis actínica.
Actinic keratosis
Adherence
Adherencia
Apoptosis
Carcinoma escamoso cutáneo
Cutaneous squamous cell carcinoma
Mecanismo de acción
Mechanism of action
Queratosis actínica
Tirbanibulin
Tirbanibulina
Journal
Actas dermo-sifiliograficas
ISSN: 1578-2190
Titre abrégé: Actas Dermosifiliogr
Pays: Spain
ID NLM: 0373062
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
07
07
2021
accepted:
18
07
2021
entrez:
7
3
2022
pubmed:
8
3
2022
medline:
8
3
2022
Statut:
ppublish
Résumé
Actinic keratosis (AK) is a skin condition characterized by the proliferation of mutated keratinocytes that can develop into squamous cell carcinoma. Available therapies, although effective, are associated with a high frequency of severe local skin reactions. Tirbanibulin, one of the treatments for AK currently in development, is a new synthetic chemical entity with anti-proliferative and anti-tumor effects, both in vitro and in vivo, with proved efficacy in the treatment of AK, which has been recently demonstrated in two phase III clinical trials. In the present review, the tirbanibulin mechanism of action, based on the relevant literature and the results of several unpublished preclinical studies, is shown. In addition, the current scenario regarding the available treatments and how the novel tirbanibulin mechanism of action fits into the treatment of AK is raised.
Identifiants
pubmed: 35249711
pii: S0001-7310(21)00298-2
doi: 10.1016/j.ad.2021.07.006
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
spa
Pagination
58-66Informations de copyright
Copyright © 2021 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.